Dr Riyaz Shah· @DrRiyazShah · X·· 1 day agoScore70
Body
KRASCENDO 1: diva v soto/adag; off inhibitor; pretreated; n338: PFS HR 0.58; 4.1m longer mPFS; OS HR 0.56; 5.7m longer OS; mDOR 11.9m ORR 58%; CNS activity not as deep; #ESMO26 @BTOGORG
38 views · 1 like · 1 repost · 0 replies
Conference abstracts
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgSource: Dr Riyaz Shah · x.com
